Palvella Therapeutics (NASDAQ:PVLA) Price Target Raised to $240.00

Palvella Therapeutics (NASDAQ:PVLA) had its price objective increased by Chardan Capital from $210.00 to $240.00 in a research report report published on Tuesday morning,Benzinga reports. Chardan Capital currently has a buy rating on the stock.

A number of other analysts also recently issued reports on PVLA. Oppenheimer reaffirmed an “outperform” rating and set a $200.00 price target on shares of Palvella Therapeutics in a report on Monday, December 15th. HC Wainwright boosted their price objective on shares of Palvella Therapeutics from $255.00 to $270.00 and gave the company a “buy” rating in a report on Tuesday, March 24th. Mizuho increased their price objective on shares of Palvella Therapeutics from $205.00 to $250.00 and gave the company an “outperform” rating in a research report on Wednesday, February 25th. Canaccord Genuity Group raised their target price on shares of Palvella Therapeutics from $148.00 to $204.00 and gave the stock a “buy” rating in a report on Tuesday, December 16th. Finally, UBS Group reaffirmed a “buy” rating and issued a $143.00 target price on shares of Palvella Therapeutics in a research report on Monday, December 15th. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $198.07.

Palvella Therapeutics Price Performance

PVLA stock opened at $123.46 on Tuesday. The stock has a market capitalization of $1.46 billion, a P/E ratio of -33.28 and a beta of -0.20. Palvella Therapeutics has a 1-year low of $18.23 and a 1-year high of $151.18. The business has a fifty day moving average price of $106.43 and a 200-day moving average price of $92.07.

Palvella Therapeutics (NASDAQ:PVLA) last released its quarterly earnings data on Tuesday, March 31st. The company reported ($1.08) EPS for the quarter, missing the consensus estimate of ($0.95) by ($0.13). As a group, analysts anticipate that Palvella Therapeutics will post -3.69 earnings per share for the current year.

Insider Activity

In other news, COO Kathleen Goin sold 4,302 shares of the company’s stock in a transaction dated Wednesday, March 18th. The shares were sold at an average price of $117.99, for a total transaction of $507,592.98. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Elaine J. Heron acquired 2,400 shares of the company’s stock in a transaction that occurred on Friday, February 27th. The stock was acquired at an average cost of $125.00 per share, for a total transaction of $300,000.00. Following the acquisition, the director owned 47,812 shares of the company’s stock, valued at $5,976,500. The trade was a 5.28% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders own 20.50% of the company’s stock.

Institutional Investors Weigh In On Palvella Therapeutics

A number of hedge funds have recently modified their holdings of PVLA. First Light Asset Management LLC purchased a new stake in shares of Palvella Therapeutics in the 3rd quarter worth $33,949,000. Summit Partners Public Asset Management LLC lifted its position in Palvella Therapeutics by 1,016.0% during the fourth quarter. Summit Partners Public Asset Management LLC now owns 389,420 shares of the company’s stock valued at $40,761,000 after purchasing an additional 354,525 shares in the last quarter. Federated Hermes Inc. bought a new stake in Palvella Therapeutics during the third quarter valued at about $21,255,000. Vanguard Group Inc. increased its position in Palvella Therapeutics by 202.0% in the third quarter. Vanguard Group Inc. now owns 494,656 shares of the company’s stock worth $31,010,000 after buying an additional 330,847 shares in the last quarter. Finally, State Street Corp increased its position in Palvella Therapeutics by 206.3% in the fourth quarter. State Street Corp now owns 420,462 shares of the company’s stock worth $44,010,000 after buying an additional 283,211 shares in the last quarter. Institutional investors own 40.11% of the company’s stock.

About Palvella Therapeutics

Palvella Therapeutics, Inc (NASDAQ: PVLA) is a clinical‐stage biopharmaceutical company devoted to the discovery and development of innovative therapies for immunological and inflammatory diseases. The company employs a proprietary small‐molecule and biologics platform to identify and modulate key molecular pathways that drive neutrophil‐ and complement‐mediated inflammation, aiming to deliver targeted treatment options for patients with significant unmet medical needs.

Palvella’s pipeline comprises several preclinical assets designed to address both prevalent chronic inflammatory conditions and rare autoinflammatory syndromes.